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Plasmid-mediated colistin After  selecting  approximately  one  third  of  our  colistin-
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Resistencia a colistina mediada por plásmido
en Escherichia coli recuperadas de aves
de corral sanas
Dear  Editor,
Several  antibiotics  have  been  massively  used  at  subin-
hibitory  concentrations  as  growth  promoters  for  more  than
6  decades3 to  improve  weight  gain  and  therefore,  to  max-
imize  feed  conversion  efﬁciency  in  animal  production.  This
use  is  currently  under  close  scrutiny,  as  it  may  be  --  and  for
sure  is  --  selecting  and  collaborating  for  multi-drug  resistant
enteric  bacteria.
As a  service  to  poultry  producers  we  have  been  moni-
toring  the  susceptibility  to  antimicrobial  agents  of  indicator
bacteria  isolated  from  intensive  farming  systems  to  support
choosing  in  advance  the  most  effective  promoters  and  to
reduce  selection  pressure.  Escherichia  coli  is  one  of  the
selected  species  considered  markers  for  antimicrobial  resis-
tance  evolution.
From  2013  to  date,  we  have  obtained  304  E.  coli  iso-
lates  recovered  from  129  broiler  chicken  farms  (only  poultry
growers)  located  in  several  provinces  of  Argentina  (Buenos
Aires,  Córdoba,  Entre  Rios,  Rio  Negro  and  Santa  Fe).  Iso-
lates  were  recovered  from  fresh  fecal  samples  collected
randomly  from  clinically  healthy  chickens  (aged  4--6  weeks).
The  analysis  showed  that  almost  half  of  them  (49%)  were
found  to  be  resistant  to  colistin,  as  determined  by  microdi-
lution  according  to  EUCAST  breakpoint  recommendations
(version  6.0).
Colistin  is  considered  a  last-line  antimicrobial  agent
retaining  activity  on  multiresistant  bacteria  recovered  from
humans.  Even  when  resistance  was  sporadically  reported,
it  was  assumed  to  be  obtained  by  mutation  of  regula-
tory  genes4.  However,  a  gene  conferring  resistance  to
colistin  was  recently  reported  in  conjugative  plasmids2.
This  gene  (mcr-1) was  most  frequently  found  in  E.  coli  but
also  in  other  species  such  as  Klebsiella  pneumoniae  and
Salmonella1.  Up  to  date,  a  large  number  of  publications
demonstrated  its  presence  in  isolates  collected  mainly  from
animal  samples,  and  to  a  lesser  extent,  in  samples  of  human
origin.
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/esistant  E.  coli, all  of  them  were  conﬁrmed  as  mcr-1
roducers  by  PCR  and  full  gene  sequencing.  In  Argentina,
he  mcr-1  determinant  was  previously  reported  in  E.  coli
linical  strains  isolated  from  inpatients5.
It  should  be  noted  that  in  our  country,  many  producers
ave  voluntarily  stopped  using  colistin  after  the  technical
eports  of  these  (our)  results,  even  before  the  initial  report
f  plasmid-borne  transmission.  In  this  regard,  the  World
ealth  Organization  recommends  that  the  use  of  colistin
e  limited  for  the  treatment  of  clinically  affected  animals.
oreover,  in  our  country,  ofﬁcial  regulations  governing  the
dministration  of  these  compounds  in  animal  feed  have
lready  changed,  including  a gradual  stepwise  process  with
 ﬁnal  goal  to  completely  ban  their  use  by  2019.
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ultiplex PCR assay for
enotyping of Mycobacterium
uberculosis in Lima, Peru
CR Múltiple para el Genotipaje de
ycobacterium tuberculosis en Lima, Perú
ear  Editor,
n  South  American  countries  it  is  necessary  to  have  molec-
lar  methods  as  epidemiological  tools  as  well  as  low  costs
nd  good  level  of  discrimination  capacity  for  polymorphisms
hat  may  enable  molecular  laboratories  to  perform  the  tasks
or  other  regional  laboratories  having  minimum  standards.
he  methodology  proposed  in  this  article  addresses  this
eed.
We  used  the  Proportion  Method2 for  susceptibility
esting  of  Mycobacterium  tuberculosis  isolates  against
soniazid  (INH),  rifampicin  (RMP),  ethambutol  (EMB),  para-
minosalicylic  acid  (PAS),  thioacetazone  (T),  kanamycin
KM)  and  streptomycin  (SM).  Cultures  were  grown  on  Low-
nstein  Jensen  medium  at  37 ◦C  for  21  days,  and  slides
ere  processed  with  the  Ziehl--Neelsen  stain.  DNA  from
amples  was  extracted  by  using  the  phenol  chloroform
ethod6.  In  a  simple  PCR  for  M.  tuberculosis  strain  dif-
erentiation,  primer  Mtb2  (5′-CGGCGGCAACGGCGGCA)  was
sed  with  primers  IS1  (5′-CGGACTCACCGGGGCGGTTCA)  and
S2  (5′-CGGACATGCCGGGGCGGTTCA)  that  anneal  at  the
nverted  repeats  ﬂanking  IS61107.  PCR  was  done  in  a  mix-
ure  containing  25  pmol  of  each  primer,  1  U  of  Platinum  Taq
NA  polymerase  (Invitrogen),  0.2  mM  of  each  deoxyribonu-
leotide  triphosphate,  10  mM  Tris--HCl  (pH  8.4),  1.65  mM
gCl2,  50  mM  KCl,  and  0.1%  Triton  X-100  and  overlaid  with
ineral  oil.  Cycling  conditions  were  as  follows:  denatur-
tion  at  94 ◦C  for  5  min,  followed  by  ampliﬁcation  for  35
ycles  of  94 ◦C  for  1  min,  62 ◦C  for  1  min,  and  72 ◦C  for  1  min,
ollowed  by  a  ﬁnal  extension  at  72 ◦C  for  10  min.  A  total
f  20  l  of  ampliﬁed  DNA  was  subjected  to  electrophore-
is  in  a  2%  agarose  gel,  detected  by  ethidium  bromide
taining,  and  visualized  under  UV  light.  For  the  genetic
olymorphism  study,  we  used  the  Bionumerics  program  ver-
10  (20.4%)  were  drug-resistant  TB  (DR)  and  21  (42.8%)  were
multidrug-resistant  TB  (MDR),  3  of  which  were  TB/HIV  cases.
Forty-two  (42)  different  banding  patterns  were  observed,
which  were  classiﬁed  into  10  clusters  (Fig.  1).  We  sus-
pect  that  cases  MT009  and  MT029  belong  to  heteroresistant
strains,  i.e.  mixed  wild-type  and  mutant  strains  because  the
banding  pattern  seems  to  overlap5.
The  transmission  study  showed  Cluster  II.  Two  male
patients  with  MDR-TB,  one  of  whom  (MT014)  had  undergone
previous  MDR-TB  treatment,  were  both  hospitalized;  Clus-
ter  IV.  Two  male  patients  with  TB/HIV  co-infection,  both
residing  in  the  same  district;  Cluster  VI.  Two  male  patients
with  TB/HIV  co-infection,  both  living  in  the  same  district
and  receiving  their  treatment  in  the  same  hospital,  one  of
them  (MT048)  with  DR  TB  and  the  other  (MT054)  with  a
sensitive  case;  Cluster  VIII.  Three  male  patients  aged  44,
34  and  28  years,  respectively,  two  of  whom  were  brothers
(MT033  and  MT041)  and  the  other  a  neighbor  (MT032),  all  of
them  sensitive  cases.  The  other  clusters  did  not  have  an  epi-
demiological  link.  A  statistical  risk  study  was  performed4,13
and  the  result  was  that  the  patients  with  HIV  infections
had  the  highest  contagion  risk  in  our  population  (p  =  0.174;
OR  =  3.150;  CI  =  0.568--17.477).  The  repetition  rate  was  good
(Cronbach’s  alpha  =  0.82).  This  genotyping  method  could  be
an  alternative  for  other  PCR-based  typing  procedures,  such
as  spoligotyping  and  MIRU-VNTR  typing  as  cited  in  other
studies7 and  could  help  in  the  study  of  transmission  relation-
ship  with  heteroresistance,  HIV-TB  patients  and  outbreaks.
Our  TB  survey  system  has  many  complications3,9,11 and  the
lack  of  surveillance  in  DOTS3 results  in  patients  having  a
great  diversity  of  genotypes  and  drug-resistant  proﬁles1,5,
as  well  as  heteroresistance  of  wild  type  to  resistant,  resis-
tant  to  resistant,  and  wild  type  to  MDR  strains1,4,8,10,12,13.  Our
country  needs  a  strategy  based  on  epidemiology  with  molec-
ular  tools  that  will  assist  us  in  the  analysis  of  the  genetic
diversity  existing  in  Peru.
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